STEPS

New Drug Reviews

Abametapir 0.74% (Xeglyze) for the Treatment of Head Lice

Meera Sunder, MD, Department of Family Medicine, Cambridge Health Alliance, Somerville, Massachusetts

Abametapir 0.74% (Xeglyze) is a topical ovicidal pediculicide labeled for the treatment of head lice infestation in patients six months and older.^{1,2}

Drug	Dosage	Dose form	Cost of full course
Abametapir (Xeglyze)	One application to head and scalp for 10 minutes	0.74% lotion	Price not yet available

Safety

No serious adverse effects were observed

in patients receiving abametapir in premarketing trials. Safety has been established in patients six months and older. Abametapir is not recommended in patients younger than six months because of a potential risk of increased systemic absorption and adverse effects caused by the inactive ingredient, benzyl alcohol. No data are available on the use of abametapir in pregnant or breastfeeding patients.

No contraindications are listed in the manufacturer labeling of abametapir. However, there is potential for inhibition of the cytochrome P450 (CYP) group of enzymes (CYP3A4, CYP3B6, CYP1A2) following a single application of abametapir, leading to possible increased systemic concentrations of medications processed by this enzyme system. The manufacturer recommends avoiding drugs metabolized by this group of enzymes within two weeks after application of abametapir. If avoidance is not possible, abametapir should not be used.¹

Tolerability

Abametapir may cause local scalp reactions in a small number of patients (less than 5%).

STEPS new drug reviews cover Safety, Tolerability, Effectiveness, Price, and Simplicity. Each independent review is provided by authors who have no financial association with the drug manufacturer.

This series is coordinated by Allen F. Shaughnessy, PharmD, assistant medical editor.

A collection of STEPS published in *AFP* is available at https://www.aafp.org/afp/steps.

Author disclosure: No relevant financial relationships.

Contact with eyes should be avoided because irritation may occur.¹

Effectiveness

In two randomized, double-blind, controlled studies involving a total of 704 patients older than six months, treatment with abametapir resulted in a greater likelihood of complete clearance of head lice at 14 days (85.9% in the treatment group vs. 61.3% in the placebo group; P < .001; number needed to treat = 4). Results were similar in children and adults.⁴

Ovicidal activity was demonstrated in a study of 50 patients. Eggs were collected before and after treatment with abametapir or vehicle. Compared with untreated eggs, the reduction in egg hatching was 92.9% for abametapir vs. 42.3% for vehicle (P < .001).² Abametapir has not been compared with other nonprescription or prescription treatments of head lice, although older treatments may have clearance rates of less than 70% following two applications.⁵

Price

Although abametapir has been approved by the U.S. Food and Drug Administration, it is not yet available in pharmacies and prices are unknown. Nonprescription treatments such as permethrin lotion or pyrethrins/piperonyl butoxide shampoo will cost about \$14 each for one bottle. Ivermectin 0.5% (Sklice) costs about \$290 for one tube (117 g).

Simplicity

Treatment involves a single application of abametapir to coat dry hair and the scalp. Abametapir should be massaged into the scalp

and hair and left on for 10 minutes before rinsing off with warm water. Contact with eyes should be avoided, and hands should be washed immediately after application. A fine-tooth or nit comb may be used to remove lice or nits. Patients may shampoo hair any time after treatment. Repeat treatment with abametapir is not necessary.¹


Bottom Line

Abametapir is shown to be an effective treatment for head lice infestation in patients six months and older. It is safer than malathion and lindane and as effective as ivermectin and spinosad. However, it is expensive compared with permethrin or other nonprescription treatments. Abametapir may be considered an alternative when other over-the-counter and less expensive treatments are ineffective or cannot be used.

Address correspondence to Meera Sunder, MD, at mesunder@challiance.org. Reprints are not available from the author.

References

- DailyMed. Drug label information. Xeglyzeabametapir lotion. Accessed February 22, 2021. https://dailymed.nlm.nih.gov/dailymed/drugInfo. cfm?setid=4fe38e95-8738-a28f-4079-43eff7318cb9
- Bowles VM, Yoon KS, Barker SC, et al. Ovicidal efficacy of abametapir against eggs of human head and body lice (Anoplura: Pediculidae) [published correction appears in J Med Entomol. 2017;54(1):248]. J Med Entomol. 2017; 54(1):167-172.
- 3. Bowles VM, Hanegraaf S, Ahveninen T, et al. Effect of a new head lice treatment, abametapir lotion, 0.74%, on louse eggs: a randomized, double-blind study. *Glob Pediatr Health*. 2019;6:2333794X19831295.
- Bowles VM, VanLuvanee LJ, Alsop H, et al. Clinical studies evaluating abametapir lotion, 0.74%, for the treatment of head louse infestation. *Pediatr Dermatol.* 2018;35(5): 616-621.
- Flores-Genuino RNS, Gnilo CMS, Dofitas BL. Occlusive versus neurotoxic agents for topical treatment of head lice infestation: a systematic review and meta-analysis. *Pediatr Dermatol.* 2020;37(1):86-92.



Use *FP Essentials* to stay up to date on family medicine

Diagnostic methods, treatments, and guidelines to keep you current, plus up to 60 Prescribed

CME credits per year

FP Essentials monthly monographs provide a comprehensive review and new information on key family medicine topics. Editions follow a three-year clinical topic cycle designed to complement the ABFM board exam format. Purchase single editions or 1 or 2-year subscriptions.

Subscribe at aafp.org/fpe



